Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 01, 2026 13:42 ET | Source: Akchuli Medical

Akchuli Medical Launches Platform to Connect Patients Directly with Doctors at Transparent, Upfront Cash Prices

New York, NY , April 01, 2026 (GLOBE NEWSWIRE) -- Akchuli Medical, a healthcare price-transparency marketplace, today announced the launch of its platform designed to connect patients directly...
March 30, 2026 07:30 ET | Source: Medicus Pharma Ltd

Medicus Pharma Reports KOL Validation of SkinJect Phase 2 Data of 80% Overall Response Rate

PHILADELPHIA, March 30, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development...
March 28, 2026 15:00 ET | Source: Biogen Inc.

Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity

In the Phase 2 part of the AMETHYST study, litifilimab met the primary endpoint of reduction of disease activity in people living with CLE at Week 16, with more litifilimab participants achieving...
March 28, 2026 11:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting

Featured presentation highlights positive BroADen Phase 1b atopic dermatitis trial results supporting KT-621’s compelling oral profile Parallel Phase 2b trials, BROADEN2 in atopic dermatitis and...
March 27, 2026 13:00 ET | Source: Monopar Therapeutics Inc.

Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update

WILMETTE, Ill., March 27, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar,” the “Company,” “we”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative...
March 27, 2026 09:00 ET | Source: Navigator Medicines INC

Navigator Medicines Advances NAV-240 into Phase 2a and NAV-242 into the Clinic, Supported by New Positive Data Presented at American Academy of Dermatology (AAD) Annual Meeting 2026

First Patient Dosed (FPD) in Phase 2a MAINSAIL Trial of NAV-240 in Hidradenitis Suppurativa (HS)Phase 1b Multiple Ascending Dose Study Demonstrates Favorable Profile for NAV-240 First Participant...
March 25, 2026 16:30 ET | Source: Custom Market Insights

[Latest] Global Sleep Tech Devices Market Size/Share Worth USD 134.60 Billion by 2035 at a 18.46% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Austin, TX, USA, March 26, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “ Size, Trends and Insights By Product (Wearables, Sleep Trackers, Smart Beds and...
March 25, 2026 08:00 ET | Source: Incannex Healthcare

Incannex Healthcare Announces Partnership with the AASM Foundation in Support of Sleep Apnea Research

MELBOURNE, Australia and NEW YORK, March 25, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing combination therapies for...
March 23, 2026 07:30 ET | Source: Cabaletta Bio

Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Rese-cel myositis BLA submission on track for 2027 based on a 17-patient, single arm registrational cohort design, including an outpatient dosing option No-preconditioning program enrolling in lupus...
March 20, 2026 06:50 ET | Source: Pharvaris N.V.

Evidence of Efficacy and Safety of Deucrictibant for Prophylaxis and On-Demand Treatment of Hereditary Angioedema Attacks Published Back-to-Back in The Lancet Haematology

Results from Phase 2 clinical studies, CHAPTER-1 and RAPIDe-1, provide evidence of viability of bradykinin B2 receptor antagonism in management of HAE ZUG, Switzerland, March 20, 2026 (GLOBE...